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ABSTRACT
Objective: In this study, the hyperthermia effect on the viability of human normal breast (MCF-10A) and cancer (MDA-MB 231 and MCF-7) cells was 
evaluated by MTT assay.
Methods: Cells were exposed to heat at 38ºC, 39ºC, 40ºC, 41ºC, 42ºC, 43ºC, and 44ºC for five different durations of heat exposure (0.5, 1, 2, 3, and 4 h). 
Breakpoint temperatures of MCF-10A, MDA-MB 231, and MCF-7 were determined using cumulative equivalent 43°C (CEM43) model. This model was 
first time used to calculate thermal isoeffect dose (TID) for MCF-10A, MDA-MB 231, and MCF-7.
Results: MCF-10A started to die at 42°C for 3 h while MDA-MB 231 and MCF-7 need a temperature of 38°C for 0.5 h; thus, they were identified as the 
threshold temperatures in CEM43 model. Furthermore, the effect of “43°C incubator 2 h” had similar total thermal dose as “44°C incubator 0.5 h” for 
MDA-MB 231 and MCF-7. In addition, “43°C incubator 3 h” effect had also almost the same thermal dose as “44°C incubator 1 h” for MDA-MB 231 and 
MCF-7.
Conclusion: A better understanding of the significant correlations between CEM43 and response parameters in clinical trials could be useful to treat 
breast cancer patients.
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INTRODUCTION
Breast cancer is a major global health problem and the most common 
invasive cancer in women of all ethnic backgrounds. Worldwide, 
estimated 1.6 million new cases are diagnosed for each year [1, 2]. 
There are many attempts with a multitude of novel therapeutic concepts 
although the conventional methods based on surgery, chemotherapy, 
radiotherapy, or their combinations steadily develop [3].
Hyperthermia among them has attracted significant attention and 
already entered clinical practice as an adjuvant to chemotherapy 
and radiotherapy [4]. It is used to raise the temperature of a region 
of the body affected by cancer with minimal or no damaging healthy 
tissues [5]. Thermal chemosensitization and thermal radiosensitization 
effects have been observed both in vivo and in in vitro cell culture 
experiments [6]. At least 18 randomized studies have demonstrated 
that the synergistic effects of combining hyperthermia with either 
chemotherapy or radiotherapy or both to achieve better therapeutic 
effects [5]. This was demonstrated for the breast, cervix, head and 
neck, pancreas, bladder, esophagus, prostate, lung, vulva/vagina 
cancers, and for melanoma. Hyperthermia has shown great potential 
in overcoming multidrug resistant (e.g. doxorubicin) which may result 
in the accumulation of chemotherapy agents within the target cells [6].
Rolf (2008) observed that synergism as a continuous change with 
increasing the rate temperatures at which cells are killed by the drug [7]. It 
is generally accepted that when temperatures are raised from 37ºC to over 
40ºC, most alkylating agents (e.g., cyclophosphamide and ifosfamide), 
platinum compounds, and nitrosoureas (bis-chloroethylnitrosourea, 
and 1-2-chloroethyl-3-cyclohexyl-1-nitrosourea) are linearly enhanced 
in their cytotoxic effect. On other the hand, threshold temperatures 
for the interaction with heat at or near 42.5ºC have a synergistic effect 
with doxorubicin or bleomycin meanwhile most antimetabolites (e.g. 
5-fluorodeoxyuridine and methotrexate), vinca alkaloids, or taxanes 
show independent action [7, 8].
Thus, thermal isoeffect dose (TID) is important because it helps to predict 
the outcome in vitro for a given heat dose. It can be applied to sensitize 
phenomena with cytostatic drugs, anticancer agents, and radiation 
therapy to improve better outcome in breast cancer treatment. The TID 
for induction of cell death was found to be closely related to the amount 
of energy required to inactivate proteins and enzymes [9]. Although the 
Arrhenius analysis could be used to calculate the inactivation energy, 
it is hard to compare two different time-temperature combinations in 
that plot. Therefore, Sapareto and Dewey [10] described the term “TID” 
(meaning two different time-temperature combinations produced 
the same cell killing effect) for comparing different time-temperature 
combinations. Calculation of the thermal dose applied in hyperthermia 
has been successfully integrated into the concept of a TID during a 
certain duration exposure at a given temperature.
Treatment outcome varied greatly between different types of cell 
lines although the same or different settings of hyperthermia used. 
For example, the proliferation of human osteosarcoma cells was 
inhibited by hyperthermia treatment at 42°C whereas heat shock at 
44°C inhibited proliferation significantly in normal fibroblasts cells [9]. 
Therefore, different mechanisms were involved in heat shock-induced 
cell death among normal cell and cancer cell [5]. According to Omar 
and Lanks [11] investigated that cancer cells are more susceptible to 
killing by heat than normal cells after the hyperthermia treatment 
(43°C–45°C).
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In the present study, it was aimed to investigate the percentage 
viability evaluated by MTT assay with time of heat treatments in breast 
carcinoma (MDA-MB 231 and MCF-7) and normal breast (MCF-10A) 
cell lines using seven different temperatures (38°C, 39°C, 40°C, 41°C, 
42°C, 43°C, and 44°C) for five different durations of heat exposure 
(0.5, 1, 2, 3, and 4 h). Moreover, breakpoint temperatures of MCF-10A, 
MDA-MB 231, and MCF-7 cells were determined using cumulative 
equivalent 43°C (CEM43) model. This model was first time used to 
calculate TID for MCF-10A, MDA-MB 231, and MCF-7 cell lines.
METHODS
Cells
The human breast cancer lines (MDA-MB 231 and MCF-7) 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 4.5 g/L glucose, 1.5 g/L sodium bicarbonate, 100 
U/mL penicillin, 100 mg/mL streptomycin, and 10% fetal calf serum. 
DMEM/Ham’s Nutrient Mixture F-12 was supplemented with 1% 
penicillin/streptomycin, 5% horse serum 1 ng/mL of cholera toxin, 
10 µg/ml of human insulin, 10 ng/ml of epidermal growth factor, and 
0.5 µg/ml of hydrocortisone which was used to culture MCF-10A cells. 
Cells were maintained in a 5% CO2 humidified incubator at 37°C.
Hyperthermic exposure
MCF-10A, MDA-MB 231, and MCF-7 cells, 1×104 cells/well in 
200 µl culture medium, were seeded in each well of 96-well plates and 
precultured overnight incubation at 37˚C. Then, hyperthermic exposure 
was performed by placing culture plates in an incubator maintained at 
38ºC, 39ºC, 40ºC, 41°C, 42°C, 43°C, and 44°C for studying cytotoxicity 
of cells. Well temperature was monitored and maintained within 0.1°C 
during the treatment period. Cultured cells were maintained at 37°C 
served as controls for all experiments. Cultured cells were subjected to 
0.5, 1, 2, 3, or 4 h of hyperthermic exposure for each temperature.
Observation under phase contrast microscope
After hyperthermia treatment, MCF-10A, MDA-MB 231, and MCF-7 cells 
were observed using a phase contrast microscope (Nikon Ti Eclipse). 
The photographs were taken at ×10/0.03 magnification.
MTT assay
MTT assay [12, 13] is a colorimetric assay for measuring the activity of 
cellular enzymes that reduce the tetrazolium dye, MTT, to its insoluble 
formazan, giving a purple color. The culture medium was removed from 
the culture plates after appropriate treatment and added with 200 µl 
of fresh culture medium and 20 μl of MTT media. The well plates were 
incubated for 4 h at 37°C. The mixture was aspirated slowly from the 
wells. Then, a volume of 200 μl of isopropanol was added to each well. 
Well plates were kept in dark for 15 minutes. Finally, absorbance at 
570 nm in each well was measured using an ELISA microplate reader 
(BioTek Instrument). This value was then background subtracted (from 
media only wells) at 650 nm and compared with controls, which are 
the values of cells without any treatment for obtaining cell growth. The 
average absorbance of the control cells exposed to free culture medium 
was set to represent 100% of viability, and the results were expressed 
as percentage of these controls.
Cell viability percentage was calculated using the following equation as 
below:
% cell viability = (Optical density of hyperthermia treated cells/Optical 
density of untreated cells) ×100%.
Statistical analysis
Results were expressed as a mean ± standard error of the mean (SEM) 
(SEM was within 5% of the average). The mean values were calculated 
from data taken from one experiment performed in triplicates. 
Significance testing was performed where indicated using one-factor 
analysis of variance. The differences were evaluated statistically 
significant at p<0.05.
Calculation of thermal isoeffect dose
The concept of a TID has been successfully integrated from the 
calculation of the thermal dose during a certain duration of heat 
exposure at a given temperature. This relationship can be expressed 
mathematically by the following isoeffect equation:
   t1=t2 * R (T2–T1) (1)
where T1 and T2 are two different temperatures of treatment and t1 and 
t2 are the duration exposure of heat at temperature T1 & T2, respectively. 
The shape of the dose-response curve is defined by empirical value, 
R. R is usually assumed as 0.5 above 43 °C and 0.25 below 43°C 
by Sapareto and Dewey [10]. Heating time periods at different 
temperatures are converted into equivalent heating minutes at 43°C 
which can be explained using the TID concept. From equation (1), if set 
T1 = 43°C and allow T2 to be varied during heat treatment, get which is 
the widely used cumulative equivalent minutes 43°C model.
  
( )43CEM R 43 T t dt= −   ∫  (2)
RESULTS AND DISCUSSION
Heat shock treatment on the viability of MCF-10A, MDA-MB 231 
and MCF-7 cell lines
In the present study, hyperthermia-induced cytotoxicity was assessed 
using MTT assay which confirmed that hyperthermia stress greatly 
decreased cell viability of MDA-MB 231 and MCF-7 cells with increasing 
temperature (from 37°C to 44°C) and duration of heat exposure (from 
1 to 4 h) while MCF-10A cells were maintained the same number as 
before hyperthermia treatment (as control) from 37°C to 42° C for 
2 h. There was a significant statistical difference when the percentage 
viability of MCF-10A, MDA-MB 231, and MCF-7 cells after the treatment 
was compared with the control (100%) (p<0.05) (Table 1). However, 
there was a mild decrease in the sum of MCF-10A viable cells as the 
duration of heat exposure increased from 2 to 3 h at the temperature 
of 42°C. Based on Table 1, MCF-10A cell viability did not cause any 
decrease compared to control (100%) from 37°C to 40°C for 0.5 to 4 h 
and 42°C for 0.5 to 2 h.
Treatment outcome varied hugely between different types of cell lines 
although the same settings of hyperthermia used. Furthermore, small 
changes in hyperthermia settings could influence greatly difference 
in the final treatment outcome. Therefore, the viability of normal and 
cancer cells is highly influenced by the temperature and duration 
exposure of heat (hyperthermia settings). For example, induction 
of apoptosis for human fibrous histiocytoma cells was inhibited 
hyperthermia treatment at 43°C for 1 h, a temperature lower than that 
was not able to induce apoptosis although increase the duration of 
heat exposure. However, Yonezawa et al. observed that necrotic death 
occurred at temperature of 46°C for 1 h where cell death was passive 
and involved lysis formation from the damaged cell and the release of its 
cellular content to the surrounding environment [14]. In contrast, heat 
shock at 44°C inhibited induction of apoptosis significantly in normal 
fibroblasts cells [9]. Therefore, different mechanisms were involved in 
heat shock-induced cell death among normal cell and cancer cells [5].
In this study, MDA-MB 231 and MCF-7 cells were started to die at 
temperature of 38°C for 0.5 h, whereas MCF-10A cell line was started 
to show cytotoxicity at 42°C for 3 h of hyperthermic exposure. It was 
reasonable because MDA-MB 231 and MCF-7 cell lines sensitive to 
heat; therefore, the facilitating effect of hyperthermia to cancer cell was 
obvious. This was due to MDA-MB 231 and MCF-7 cells did not have a 
defense system against heat, as did MCF-10A cells [15]. MCF-10A might 
express heat shock-induced proteins to reactivate denatured proteins; 
degrade abnormally structured proteins; and inhibit secretion of 
abnormal proteins and assisting the transfer of secretory proteins by 
blockage of folding [16]. In addition, Hsp70 induction by hyperthermia 
treatment in cancer cells is lower than those in normal cells [17].
514
Asian J Pharm Clin Res, Vol 12, Issue 3, 2019, 512-515
 Elengoe et al. 
Therefore, MCF-10A cells were survived in undesirable circumstances 
such as at 42°C incubator hyperthermia for 2 h. However, cell death 
of MCF-10A cells occurred when temperature increased to 42°C (>2 h 
of heat exposure). MCF-10A, MDA-MB 231, and MCF-7 cells might die 
exponentially by induction of apoptosis where cell death was active. 
When the temperature and duration exposure continued to increase, 
the cellular proteins denature at that high temperature and the cell 
dies passively (necrosis) before initiation of apoptosis for an extreme 
condition such as hyperthermia treatment on MDA-MB 231 and 
MCF-7 cells at a temperature of 44°C for 4 h. In this study, normal cell 
line might die exponentially by induction of apoptosis but they might 
not reach until necrosis. Based on Gabai and Kabakov study [18], 
cytoskeleton damages and impairment of DNA repair system caused 
by hyperthermia treatment most likely occur during mitosis; therefore, 
MDA-MB 231 and MCF-7 (cancer) cells were more susceptible to 
heat than MCF-10A (normal) cell as cancer cells underwent faster 
cell division than normal cells. According to Watanabe and Suzuki 
(1989) [19], normal cells have reduced heat sensitivities 5–6 times at 
growing condition while cancer did not.
Although cancer therapies such as chemotherapy and radiotherapy can 
induce tumor cell apoptosis, physiological stress conditions such as 
growth factor, starvation, hypoxia, or heat can also be equally effective 
to DNA damaging treatment [20]. Abnormalities of these environmental 
factors affect tumor cell proliferation and response to antitumor therapy. 
Tumor cells with a disorganized and compact vascular structure have 
difficulty dissipating heat. Thus, hyperthermia might cause cancer cells 
to undergo apoptosis in direct response to heat. In contrast, healthy 
cells can more easily maintain at a normal temperature. Based on 
Urano et al. 1983 study [21], tumor cells might be more sensitive to 
lower temperature than normal tissue. Results from this study proved 
that Urano’s hypothesis was right where MDA-MB 231 and MCF-7 cells 
were sensitive to the temperature of 38°C. Besides that, as shown in 
Song et al.’s study [22], rat muscle and skin have a greatly enhanced 
blood flow at temperatures above 42°C while tumors have a greatly 
reduced blood flow at these temperatures. Reduction of blood flow 
and blood vessel density, resulting in regions with hypoxia and low 
pH levels, which is not found in normal tissues under undisturbed 
conditions. Hypoxia might exhibit anaerobic metabolism with resultant 
accumulation of lactic acid [23]. Acute acidification pH increases the 
rate of cell death by decrease heat shock protein levels [24].
CONCLUSION
The temperature of 42°C for 2 h was chosen as the most suitable 
temperature and duration of heat exposure to kill cancer cells (MDA-
MB 231 and MCF-7) without damaging normal cells (MCF-10A).
Calculation of thermal isoeffect dose
Cell death of MCF-10A, MDA-MB 231, and MCF-7 cell lines from 37°C 
to 44°C for 0.5 h up to 4 h was studied. When exponentially growing 
cultured cells (MCF-10A, MDA-MB 231, and MCF-7) were exposed to a 
defined temperature between 37°C and 44°C of heat exposure, a dose-
effect curve was defined by plotting the rate of cell viability against the 
duration of hyperthermia. The survival curves of MDA-MB 231 and 
MCF-7 cell lines show a linear growth arrest at the beginning of heat 
exposure which reflecting reversible and nonlethal heat damage and 
then, followed by exponential cell death. This is typical “shoulder” which 
reflects a two-step process of cell killing. However, after increasing the 
temperature to 43°C, more cells were killed during the same period of 
heat exposure. Therefore, it was concluded that once the hyperthermia 
treatment starts to show cytotoxicity, the rate of cell death, which is 
exponential with exposure duration, is dependent on the temperature 
of exposure [25].
Arrhenius plot is hard to use for compare two different time-
temperature combinations. Thus, the term “TID” (meaning two different 
time-temperature combinations produced the same cell killing effect) 
was proposed by Sapareto and Dewey for comparing different time-
temperature combinations [10]. The thermal dose can be described 
as the cumulative equivalent minutes at 43°C for any hyperthermia 
treatment.
In this study, MDA-MB 231 and MCF-7 cells need temperature of 
38°C for 0.5 h to induce apoptosis; therefore, it was identified as the 
threshold temperature in CEM43 model. For MCF-10A cell line, it was 
clearly indicated that a 42°C hyperthermia treatment for 3 h started to 
show very little cytotoxicity (Table 1), so the breakpoint for MCF-10A 
was at temperature of 42°C for 3 h.
Table 2 shows calculated CEM43 for several different types of 
hyperthermia treatment based on the survival curves and Equation 
2. As a result, the thermal dose (killing effect) of MCF-10A was lower 
than MDA-MB 231 and MCF-7 although same settings of hyperthermia 
used. Effect of “43°C incubator 2 h” had similar total thermal dose as 
“44°C incubator 0.5 h” for MDA-MB 231 and MCF-7 cells. In addition, 
“43°C incubator 3 h” effect had also almost the same thermal dose 
as “44°C incubator 1 h” for MDA-MB 231 and MCF-7 cell lines. This was 
defined as TID.
The thermal energy dose was required to induce exponential cell death 
(inactivation energy) which is closely correlated to that required for 
cellular proteins and enzymes denaturation [10]. It can be combined 
with cytostatic drugs (e.g. 5-fluorouracil, melphalan, and paclitaxel), 
Table 1: Cell viability percentage of MCF-10A, MDA-MB 231, and MCF-7 following heat treatmenta
Cells Time (hours) 38°C 39°C 40°C 41°C 42°C 43°C 44°C
MCF-10A 0 100±0.086b 99.916±0.251b 99.815±0.185b 100±0.172b 100±0b 100±0.504b 100±0.095b
0.5 99.914±0.086 99.916±0.168 99.908±0.277 99.914±0.172 100±0* 99.496±0.504 97.533±0.19
1 99.829±0.342* 99.916±0.168 100±0.185* 99.828±0.172* 100±0.19 98.69±0.604 93.074±0.38
2 99.914±0.171 99.916±0.251 99.908±0.185* 99.914±0.172 100±0* 96.979±0.705 89.943±0.095*
3 100±0.086 99.916±0.168 99.908±0.185 99.914±0.086 100±0.095 95.77±0.302 87.192±0.285*
4 99.914±0.086 99.916±0.168 100±0.092 99.914±0.258 100±0* 91.339±0.403 81.12±0.19*
MDA-MB 231 0 100±1.221b 100±0.592b 100±0.548b 100±1.261b 100±1.469b 100±0.412b 100±0.105b
0.5 97.447±0.888* 95.008±1.110 94.189±1.316 93.277±0.840 91.081±1.154 78.991±0.515 67.613±0.210
1 94.229±1.221 92.470±0.761* 90.351±1.206* 87.605±1.261* 83.736±1.889* 62.822±0.412* 47.950±0.210*
2 92.231±2.109* 89.932±0.761* 85.417±2.083* 79.892±3.466* 76.390±1.889* 52.317±1.339* 35.331±0.315*
3 84.795±1.554* 79.019±1.523* 67.325±4.605* 55.042±1.786* 46.065±3.148* 27.909±0.515* 10.410±0.210*
4 69.256±2.331* 55.076±0.592* 43.860±4.057* 29.412±3.027* 16.159±2.833* 9.784±0.515* 0.421±0.315*
MCF-7 0 100±1.378b 100±0.347b 100±2.286b 100±1.038b 100±3.769b 100±0.418b 100±0.815b
0.5 98.163±0.459 96.412±0.347 94.857±1.029 95.386±0.692 92.108±1.413 79.937±0.418 68.685±0.931
1 96.326±0.689* 94.290±0.694* 91.886±2.286* 89.043±2.653 86.219±3.534* 64.159±0.627* 49.942±3.492*
2 93.226±1.378* 90.509±1.505* 86.629±2.857* 82.122±2.191* 80.448±1.885* 53.083±1.149* 43.772±2.678*
3 88.634±2.526* 80.093±1.157 68.914±2.286* 58.362±2.307 49.234±3.062* 29.467±0.522* 15.483±2.678*
4 71.642±3.674* 57.639±2.894* 44.686±2.626* 31.949±2.884* 19.317±3.887* 11.494±0.418* 1.513±1.048*
aValues represent mean±SD of three measurements from one independent experiment, bThe viability of MCF-10A, MDA-MB 231 and MCF-7 cells at 37°C as control, 
*p<0.05. SD: Standard deviation
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anticancer agents, radiation, gene, and immunotherapy to achieve 
better outcome in breast cancer treatment. For example, the use of 
simultaneous application of weekly cisplatin and regional hyperthermia 
resulted in a 50% response rate. However, the response rate was about 
15% without regional hyperthermia for patients with locoregional 
advanced cervix carcinoma in a clinical trial. A better understanding of 
the significant correlations between CEM43 and response parameters in 
clinical trials could useful to treat breast cancer patients.
AUTHOR’S CONTRIBUTIONS
AE designed the research, performed the experiments, analyzed 
data, and wrote the paper. NJBMA provided the MCF-10A cells. SH 
contributed critical comments and suggestions. All authors read and 
approved the final manuscript.
CONFLICTS OF INTERESTS
All authors of this publication declare that there are no conflicts of 
interest in publishing this research article.
REFERENCES
1. American Cancer Society. Cancer Facts and Figures. Atlanta, Georgia: 
American Cancer Society; 2014.
2. Rukminingsih F, Andayani TM, Rahmawati F, Widayati K. Health-
related quality of life in early breast cancer patients with hormone 
responsive. Int J Pharm Pharm Sci 2018;10:47-9.
3. Al Rashid MD, Bharawaj PV, Majumder S, Mandal V, Pal M, 
Mandal SC, et al. Antioxidant and anticancer activty of extract and 
fractions obtained from Diospyros melanoxylon roxb. leaves and 
correlation with their polyphenolic profiles. Int J Pharm Pharm Sci 
2018;10:7-16.
4. Chalkidou A, Simeonidis K, Angelakeris M, Samaras T, Martinez-
Boubeta C, Balcells, L. In vitro application of Fe/MgO nanoparticles 
as magnetically mediated hyperthermia agents for cancer treatment. 
J Magn Magn Mater 2011;323:775-80.
5. van der Zee J. Heating the patient: A promising approach? Ann Oncol 
2002;13:1173-84.
6. Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, 
et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol 
Hematol 2002;43:33-56.
7. Issels RD. Hyperthermia adds to chemotherapy. Eur J Cancer 
2008;44:2546-54.
8. Urano M, Kuroda M, Nishimura Y. For the clinical application of 
thermochemotherapy given at mild temperatures. Int J Hyperthermia 
1999;15:79-107.
9. Morris CC, Myers R, Field SB. The response of the rat tail to 
hyperthermia. Br J Radiol 1977;50:576-80.
10. Sapareto SA, Dewey WC. Thermal dose determination in cancer 
therapy. Int J Radiat Oncol Biol Phys 1984;10:787-800.
11. Omar RA, Lanks KW. Heat shock protein synthesis and cell survival in 
clones of normal and simian virus 40-transformed mouse embryo cells. 
Cancer Res 1984;44:3976-82.
12. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, 
et al. Feasibility of drug screening with panels of human tumor cell lines 
using a microculture tetrazolium assay. Cancer Res 1988;48:589-601.
13. Muruganandam L, Maheswari R. Anti-cancer studies of selective 
mannich bases by in silico method. Int J Curr Pharm Res 2018;10:81-5.
14. Yonezawa M, Otsuka T, Matsui N, Tsuji H, Kato KH, Moriyama A, 
et al. Hyperthermia induces apoptosis in malignant fibrous histiocytoma 
cells in vitro. Int J Cancer 1996;66:347-51.
15. Fukao H, Ikeda M, Ichikawa T, Inufusa H, Okada K, Ueshima S, et al. 
Effect of hyperthermia on the viability and the fibrinolytic potential of 
human cancer cell lines. Clin Chim Acta 2000;296:17-33.
16. Ellis RJ, van der Vies SM. Molecular chaperones. Annu Rev Biochem 
1991;60:321-47.
17. Williams RS, Thomas JA, Fina M, German Z, Benjamin IJ. Human 
heat shock protein 70 (hsp70) protects murine cells from injury during 
metabolic stress. J Clin Invest 1993;92:503-8.
18. Gabai VL, Kabakov AE. Tumor cell resistance to energy deprivation 
and hyperthermia can be determined by the actin skeleton stability. 
Cancer Lett 1993;70:25-31.
19. Watanabe M, Suzuki K. Heat sensitivity of human cancer cells 
and abnormal expression of heat shock protein 70. Gan No Rinsho 
1989;35:1512-6.
20. Takasu T, Lyons JC, Park HJ, Song CW. Apoptosis and perturbation 
of cell cycle progression in an acidic environment after hyperthermia. 
Cancer Res 1998;58:2504-8.
21. Urano M, Rice L, Epstein R, Suit HD, Chu AM. Effect of whole-body 
hyperthermia on cell survival, metastasis frequency, and host immunity 
in moderately and weakly immunogenic murine tumors. Cancer Res 
1983;43:1039-43.
22. Song CW, Lokshina A, Rhee JG. Implication of blood flow in 
hyperthermic treatment of tumors. IEEE Trans BME 1984;31:9-16.
23. Marder J, Eylath U, Moskovitz E, Sharir R. The effect of heat exposure 
on blood chemistry of the hyperthermic rabbit. Comp Biochem Physiol 
A Comp Physiol 1990;97:245-7.
24. Han JS, Storck CW, Wachsberger PR. Acute extracellular acidification 
increases nuclear associated protein levels in human melanoma cells 
during 42°C hyperthermia and enhances cell killing. Int J Hyperthermia 
2002; 18: 404-15.
25. Dewhirst MW, Viglianti BL, Lora-Michiels M, Hanson M, Hoopes PJ. 
Basic thermal dosimetry and thermal thresholds for tissue damage from 
hyperthermia. Int J Hyperthermia 2003;19:267-94.
Table 2: Equivalent heating minutes at 43°C using thermal 
isoeffective dose concept
Cell Treatment CEM43 (min)
MCF-10A 43°C incubator 0.5 h 0.065
43°C incubator 1 h 0.331
43°C incubator 2 h 1.675
43°C incubator 3 h 8.486
43°C incubator 4 h 19.102
MCF-10A 44°C incubator 0.5 h 0.659
44°C incubator 1 h 2.680
44°C incubator 2 h 10.216
44°C incubator 3 h 34.622
44°C incubator 4 h 69.030
MDA-MB 231 43°C incubator 0.5 h 52.431
43°C incubator 1 h 63.931
43°C incubator 2 h 95.051
43°C incubator 3 h 141.318
43°C incubator 4 h 210.107
MDA-MB 231 44°C incubator 0.5 h 93.009
44°C incubator 1 h 196.604
44°C incubator 2 h 329.430
44°C incubator 3 h 490.662
44°C incubator 4 h 685.129
MCF-7 43°C incubator 0.5 h 54.478
43°C incubator 1 h 69.021
43°C incubator 2 h 110.788
43°C incubator 3 h 177.830
43°C incubator 4 h 285.441
MCF-7 44°C incubator 0.5 h 96.340
44°C incubator 1 h 211.158
44°C incubator 2 h 380.008
44°C incubator 3 h 607.891
44°C incubator 4 h 911.654
Calculated CEM43 for different types of hyperthermia treatment for MCF-10A, 
MDA-MB 231, and MCF-7 cell lines
